Macrophages kill human papillomavirus type 16 e6-expressing tumor cells by tumor necrosis factor alpha- and nitric oxide-dependent mechanisms

Journal of Virology

Volumn 79, Issue 1, 2005, Pages 116-123

  Routes, John M ^a,b   Morris, Kristin ^a   Ellison, Misoo C ^a,b   Ryan, Sharon ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1A PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MUTANT PROTEIN; NITRIC OXIDE; PROTEIN E6; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS 2; ADENOVIRUS 5; ARTICLE; CELL IMMORTALIZATION; CYTOLYSIS; MACROPHAGE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SEROTYPING; TUMOR CELL; VIRUS EXPRESSION; WART VIRUS;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; HUMANS; KILLER CELLS, NATURAL; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NITRIC OXIDE; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 10644279845     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.1.116-123.2005     Document Type: Article

References (81)

1. Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner. 1994. E1A-associated p300 and CREB-assoeiated CBP belong to a conserved family of coactivators. Cell 77:799-800.
2. Bernat, A., N. Avvakumov, J. S. Mymryk, and L. Banks. 2003. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 22:5927-5937.
3. Bernat, A., P. Massimi, and L. Banks. 2002. Complementation of a p300/CBP defective-binding mutant of adenovirus E1a by human papillomavirus E6 proteins. J. Gen. Virol. 83:829-833.
4. Bosch, F. X., M. M. Manos, N. Mun̄oz, M. Sherman, A. M. Jansen, J. Peto, M. H. Schiffman, V. Moreno, R. Kurman, and K. V. Shah. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87:796-802.
5. Brokaw, J. L., C. L. Yee, and K. Münger. 1994. A mutational analysis of the amino terminal domain of the human papillomavirus type 16 E7 oncoprotein. Virology 205:603-607.
6. Chinnadurai, G. 2004. Modulation of oncogenic transformation by the human adenovirus E1A C-terminal region. Curr. Top. Microbiol. Immunol. 273:139-161.
7. Cook, J. L., J. B. Hibbs, Jr., and A. M. Lewis, Jr. 1982. DNA virus-transformed hamster cell-host effector cell interactions: level of resistance to cytolysis correlated with tumorigenicity. Int. J. Cancer 30:795-803.
8. Cook, J. L., C. K. Krantz, and B. A. Routes. 1996. Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection. Proc. Natl. Acad. Sci. USA 93:13985-13990.
9. Cook, J. L., D. L. May, B. A. Wilson, B. Holskin, M. J. Chen, D. Shalloway, and T. A. Walker. 1989. Role of tumor necrosis factor-alpha in E1A oncogene-induced susceptibility of neoplastic cells to lysis by natural killer cells and activated macrophages. J. Immunol. 142:4527-4534.
10. Cook, J. L., T. A. Miura, D. N. Ikle, A. M. Lewis, Jr., and J. M. Routes. 2003. E1A oncogene-induced sensitization of human tumor cells to innate immune defenses and chemotherapy-induced apoptosis in vitro and in vivo. Cancer Res. 63:3435-3443.
11. Cook, J. L., T. A. Potter, D. Bellgrau, and B. A. Routes. 1996. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes. Oncogene 12:833-842.
12. Cook, J. L., B. A. Routes, C. Y. Leu, T. A. Walker, and K. L. Colvin. 1999. E1A oncogene-induced cellular sensitization to immune-mediated apoptosis is independent of p53 and resistant to blockade by E1B 19 kDa protein. Exp. Cell Res. 252:199-210.
13. Cook, J. L., B. A. Routes, T. A. Walker, K. L. Colvin, and J. M. Routes. 1999. E1A oncogene induction of cellular susceptibility to killing by cytolytic lymphocytes through target celt sensitization to apoptotic injury. Exp. Cell Res. 251:414-423.
14. Cook, J. L., T. A. Walker, A. M. Lewis, Jr., H. E. Ruley, F. L. Graham, and S. H. Pilder. 1986. Expression of the adenovirus E1A oncogene during cell transformation is sufficient to induce susceptibility to lysis by host inflammatory cells. Proc. Natl. Acad. Sci. USA 83:6965-6969.
15. Cook, J. L., T. A. Walker, G. S. Worthen, and J. R. Radke. 2002. Role of the E1A Rb-binding domain in repression of the NF-κB-dependent defense against tumor necrosis factor-alpha. Proc. Natl. Acad. Sci. USA 99:9966-9971.
16. Day, D. B., N. A. Zachariades, and L. R. Gooding. 1994. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell. Immunol. 157:223-238.
17. de Belle, I., R. P. Huang, Y. Fan, C. Liu, D. Mercola, and E. D. Adamson. 1999. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene 18:3633-3642.
18. Duerksen-Hughes, P., W. S. M. Wold, and L. R. Gooding. 1989. Adenovirus E1A renders infected cells sensitive to cytolysis by tumor necrosis factor. J. Immunol. 143:4193-4200.
19. Duerksen-Hughes, P. J., J. Yang, and S. B. Schwartz. 1999. HPV 16 E6 blocks TNF-mediated apoptosis in mouse fibroblast LM cells. Virology 264:55-65.
20. Dyson, N., P. Guida, K. Münger, and E. Harlow. 1992. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. J. Virol. 66:6893-6902.
21. Eckner, R., M. E. Ewen, D. Newsome, M. Gerdes, J. A. DeCaprio, J. B. Lawrence, and D. M. Livingston. 1994. Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev. 8:869-884.
22. Eckner, R., J. W. Ludlow, N. L. Lill, E. Oldread, Z. Arany, N. Modjtahedi, J. A. DeCaprio, D. M. Livingston, and J. A. Morgan. 1996. Association of p300 and CBP with simian virus 40 large T antigen. Mol. Cell. Biol. 16:3454-3464.
23. Erwig, L. P., D. C. Kluth, G. M. Walsh, and A. J. Rees. 1998. Initial cytokine exposure determines function of macrophages and renders them unresponsive to other cytokines. J. Immunol. 161:1983-1988.
24. Feltkamp, M. C., G. R. Vreugdenhil, M. P. Vierboom, E. Ras, S. H. van der Burg, J. ter Schegget, C. J. Melief, and W. M. Kast. 1995. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur. J. Immunol. 25:2638-2642.
25. Filippova, M., L. Parkhurst, and P. J. Duerksen-Hughes. 2004. The human papillomavirus 16 E6 protein binds to FADD and protects cells from Fas-triggered apoptosis. J. Biol. Chem. 279:25729-25744.
26. Filippova, M., H. Song, J. L. Connolly, T. S. Dermody, and P. J. Duerksen-Hughes. 2002. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J. Biol. Chem. 277:21730-21739.
27. Frisch, S. M. 1991. Antioncogenic effect of adenovirus E1A in human tumor cells. Proc. Natl. Acad. Sci. USA 88:9077-9081.
28. Gaiotti, D., J. Chung, M. Iglesias, M. Nees, P. D. Baker, C. H. Evans, and C. D. Woodworth. 2000. Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol. Carcinog. 27:97-109.
29. Goodman, R. H., and S. Smolik. 2000. CBP/p300 in cell growth, transformation, and development. Genes Dev. 14:1553-1577.
30. Graham, F. L., J. Smiley, W. C. Russell, and R. Nairn. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36:59-72.
31. Green, M., W. Wold, J. Mackey, and P. Rigden. 1979. Analysis of human tonsil and cancer DNAs and RNAs for DNA sequences of group C (serotypes 1, 2, 5 and 6) human adenovirus. Proc. Natl. Acad. Sci. USA 76:6606-6610.
32. Halbert, C., G. Demers, and D. Galloway. 1991. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol. 65:473-478.
33. Hassa, P. O., C. Buerki, C. Lombardi, R. Imhof, and M. O. Hottiger. 2003. Transcriptional coactivation of NF-κB-dependent gene expression by p300 is regulated by PARP-1. J. Biol. Chem. 278:45145-45153.
34. Helt, A. M., and D. A. Galloway. 2003. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24:159-169.
35. Higuchi, M., N. Higashi, H. Taki, and T. Osawa. 1990. Cytolytic mechanisms of activated macrophages. Tumor necrosis factor and L-arginine-dependent mechanisms act synergistically as the major cytolytic mechanisms of activated macrophages. J. Immunol. 144:1425-1431.
36. Kägi, D., B. Ledermann, K. Bürki, P. Seiler, B. Odermatt, K. J. Olsen, E. R. Podack, R. M. Zinkernagel, and H. Hengartner. 1994. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37.
37. Kao, W. H., S. L. Beaudenon, A. L. Talis, J. M. Huibregtse, and P. M. Howley. 2000. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase. J. Virol. 74:6408-6417.
38. Keller, R., R. Keist, A. Wechsler, T. P. Leist, and P. H. van der Meide. 1990. Mechanisms of macrophage-mediated tumor cell killing: a comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor. Int. J. Cancer 46:682-686.
39. Klefstrom, J., P. E. Kovanen, K. Somersalo, A. O. Hueber, T. Littlewood, G. I. Evan, A. H. Greenberg, E. Saksela, T. Timonen, and K. Alitalo. 1999. c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. Oncogene 18:2181-2188.
40. Krantz, C. K., B. A. Routes, M. P. Quinlan, and J. L. Cook. 1996. E1A second exon requirements for induction of target cell susceptibility to lysis by natural killer cells: implications for the mechanism of action. Virology 217:23-32.
41. Lewis, A. M., Jr., and J. L. Cook. 1985. A new role for DNA virus early proteins in viral carcinogenesis. Science 227:15-20.
42. Liu, Y., Y. Hong, E. J. Androphy, and J. J. Chen. 2000. Rb-independent induction of apoptosis by bovine papillomavirus type 1 E7 in response to tumor necrosis factor alpha. J. Biol. Chem. 275:30894-30900.
43. Liu, Y., V. Tergaonkar, S. Krishna, and E. J. Androphy. 1999. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. J. Biol. Chem. 274:24819-24827.
44. MacMicking, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15:323-350.
45. Madrid, L. V., M. W. Mayo, J. Y. Reuther, and A. S. Baldwin, Jr. 2001. Akt simulates the transactivation potential of the RelA/p65 subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J. Biol. Chem. 276:18934-18940.
46. Melero, I., M. C. Singhal, P. McGowan, H. S. Haugen, J. Blake, K. E. Hellstrom, G. Yang, C. H. Clegg, and L. Chen. 1997. Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J. Virol. 71:3998-4004.
47. Miura, T. A., H. Li, K. Morris, S. Ryan, K. Hembre, J. L. Cook, and J. M. Routes. 2004. Expression of an E1A/E7 chimeric protein sensitizes tumor cells to killing by activated macrophages but not NK cells. J. Virol. 78:4646-4654.
48. Miura, T. A., K. Morris, S. Ryan, J. L. Cook, and J. M. Routes. 2003. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein. J. Immunol. 170:4119-4126.
49. Mule, J. J., J. C. Yang, R. L. Afreniere, S. Shu, and S. A. Rosenberg. 1987. Identification of cellular mechanisms operational in vivo during regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. J. Immunol. 139:285-294.
50. Munger, K., J. R. Basile, S. Duensing, A. Eichten, S. L. Gonzalez, M. Grace, and V. L. Zacny. 2001. Biological activities and molecular targets of the human papillomavirus E7 oncoprotein. Oncogene 20:7888-7898.
51. Münger, K., W. Phelps, V. Bubb, P. Howley, and R. Schlegel. 1989. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J. Virol. 63:4417-4421.
52. Münger, K., C. Yee, W. Phelps, J. Pietenpol, H. Moses, and P. Howley. 1991. Biochemical and biological differences between E7 oncoproteins of the high-and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 65:3943-3948.
53. Munoz, N., F. X. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. V. Shah, P. J. Snyders, and C. J. Meyer. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
54. Mymryk, J. S., and S. T. Bayley. 1993. Induction of gene expression by exon 2 of the major E1A proteins of adenovirus type 5. J. Virol. 67:765-775.
55. Patel, D., S. M. Huang, L. A. Baglia, and D. J. McCance. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J. 18:5061-5072.
56. S. J. Virol. 77:2651-2662.
57. Perkins, N. D., L. K. Felzien, J. C. Betts, K. Leung, D. H. Beach, and G. J. Nabel. 1997. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275:523-527.
58. Phelps, W. C., C. L. Yee, K. Münger, and P. M. Howley. 1988. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53:539-547.
59. Rapp, L., Y. Liu, Y. Hong, E. J. Androphy, and J. J. Chen. 1999. The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis. Oncogene 18:607-615.
60. 1 in transformed cells elicits cytolytic response in syngeneic rats. Virology 117:530-535.
61. Routes, J., S. Ryan, A. Clase, T. Miura, A. Kuhl, T. A. Potter, and J. A. Cook. 2000. Adenovirus E1A oncogene expression in tumor cells enhances killing by TNF-related apoptosis-inducing ligand (TRAIL). J. Immunol. 165:4522-4527.
62. Routes, J. M., H. Li, S. T. Bayley, S. Ryan, and D. J. Klemm. 1996. Inhibition of IFN-stimulated gene expression and IFN induction of cytolytic resistance correlate with E1A-p300 binding. J. Immunol. 156:1055-1061.
63. Routes, J. M., and S. Ryan. 1995. Oncogenicity of human papillomavirus- or adenovirus-transformed cells correlates with resistance to lysis by natural killer cells. J. Virol. 69:7639-7647.
64. Routes, J. M., S. Ryan, J. Steinke, and J. L. Cook. 2000. Dissimilar immunogenicities of human papillomavirus E7 and adenovirus E1A proteins influence primary tumor development. Virology 277:48-57.
65. Ruley, H. E., J. Moomaw, C. Chang, J. I. Garrels, M. Furth, and B. R. Franza. 1985 Multistep transformation of an established cell line by the adenovirus E1A and T24 Ha-ras-1 genes, p. 257-264. In J. Feramisco, B. Ozanne, and C. Stiles (ed.), Cold Spring Harbor symposia on quantitative biology. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
66. Sabbatini, P., S. K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell. Biol. 15:1060-1070.
67. Sawada, Y., B. Fohring, T. E. Shenk, and K. Raska, Jr. 1985. Tumorigenicity of adenovirus-transformed cells; region E1A of adenovirus 12 confers resistance to natural killer cells. Virology 147:413-421.
68. Scheffner, M., B. Werness, J. Huibregtse, A. Levine, and P. Howley. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
69. Scott, M. J., J. J. Both, S. A. Gardner, J. C. Peyton, and W. G. Cheadle. 2003. Natural killer cell activation primes macrophages to clear bacterial infection. Am. Surg. 69:679-687.
70. Shao, R., M. C. Hu, B. P. Zhou, S. Y. Lin, P. J. Chiao, R. H. von Lindern, B. Spohn, and M. C. Hung. 1999. E1A sensitizes cells to tumor necrosis factor-induced apoptosis through inhibition of IκB kinases and nuclear factor ê activities. J. Biol. Chem. 274:21495-21498.
71. Shao, R., D. Karunagaran, B. P. Zhou, K. Li, S. S. Lo, J. Deng, P. Chiao, and M. C. Hung. 1997. Inhibition of nuclear factor-κB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis. J. Biol. Chem. 272:32739-32742.
72. Spitkovsky, D., S. P. Hehner, T. G. Hofmann, A. Moller, and M. L. Schmitz. 2002. The human papillomavirus oncoprotein E7 attenuates NF-κB activation by targeting the IκB kinase complex. J. Biol. Chem. 277:25576-25582.
73. + T-cell responses in mice expressing human papillomavirus type 16 E7 oncoprotein from the keratin-14 promoter. J. Virol. 75:5985-5997.
74. + T cell responses in women with high grade vulvar intraepithelial neoplasia. Int. J. Cancer 108:857-862.
75. Vikhanskaya, F., C. Falugi, P. Valente, and P. Russo. 2002. Human papillomavirus type 16 E6-enhanced susceptibility to apoptosis induced by TNF in A2780 human ovarian cancer cell line. Int. J. Cancer 97:732-739.
76. Villarete, L. H., and D. G. Remick. 1995. Nitric oxide regulation of IL-8 expression in human endothelial cells. Biochem. Biophys. Res. Commun. 211:671-676.
77. Vousden, H. K., and P. S. Jat. 1989. Functional similarity between HPV16 E7, SV40 large T and adenovirus E1a proteins. Oncogene 4:153-158.
78. Walker, T. A., B. A. Wilson, A. M. Lewis, Jr., and J. L. Cook. 1991. E1A oncogene induction of cytolytic susceptibility eliminates sarcoma cell tumorigenicity. Proc. Natl. Acad. Sci. USA 88:6491-6495.
79. Werness, B. A., A. J. Levine, and P. M. Howley. 1990. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76-79.
80. Yew, P. J., and A. J. Berk. 1992. Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature (London) 357:82-85.
81. Zimmermann, H., R. Degenkolbe, H. U. Bernard, and M. J. O'Connor. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J. Virol. 73:6209-6219.